| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | RCA1; VHL1; pVHL; HRCA1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human VHL |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于VHL抗体的参考文献示例(注：以下内容为假设性示例，建议通过学术数据库核实具体文献)：
---
1. **文献名称**: *"Development and Validation of a Novel Monoclonal Antibody for Detecting VHL Protein in Renal Cell Carcinoma"*
**作者**: Smith A, et al.
**摘要**: 本研究报道了一种高特异性的抗VHL单克隆抗体的开发，验证其在肾透明细胞癌组织中的免疫组化应用，证明其可有效检测VHL蛋白的缺失，为VHL相关肿瘤的诊断提供工具。
2. **文献名称**: *"VHL Antibody-Based Profiling of HIF-1α Degradation Pathways in Hypoxic Conditions"*
**作者**: Lee B, et al.
**摘要**: 通过使用抗VHL抗体进行免疫沉淀分析，揭示了缺氧条件下VHL蛋白调控HIF-1α泛素化降解的分子机制，为靶向HIF通路的癌症治疗提供理论依据。
3. **文献名称**: *"A Comparative Study of Commercial VHL Antibodies in Clinical Biomarker Assays"*
**作者**: Johnson C, et al.
**摘要**: 对比分析了多种市售VHL抗体的灵敏度和特异性，提出标准化检测方案，强调抗体选择对VHL相关疾病(如嗜铬细胞瘤)分子分型的重要性。
4. **文献名称**: *"Targeted Delivery of Therapeutic Agents Using Anti-VHL Antibody Conjugates"*
**作者**: Chen D, et al.
**摘要**: 开发了基于VHL抗体的药物偶联物，证明其可特异性靶向VHL缺陷型肿瘤细胞，并在小鼠模型中显著抑制肿瘤生长，展示潜在治疗应用价值。
---
建议通过 **PubMed** 或 **Web of Science** 检索真实文献，关键词如“VHL antibody”、“anti-VHL antibody application”等，以获取具体研究内容。
**Background of VHL Antibodies**
VHL (von Hippel-Lindau) antibodies are essential tools for studying the VHL protein, encoded by the *VHL* tumor suppressor gene located on chromosome 3p25.3. The VHL protein (pVHL) is a critical component of the E3 ubiquitin ligase complex, which targets hypoxia-inducible factors (HIF-1α and HIF-2α) for proteasomal degradation under normoxic conditions. This regulation prevents aberrant activation of hypoxia-responsive genes involved in angiogenesis, cell proliferation, and metabolism.
Mutations or deletions in the *VHL* gene disrupt this process, leading to HIF accumulation and promoting tumorigenesis. VHL dysfunction is hallmark of von Hippel-Lindau disease, a hereditary cancer syndrome predisposing individuals to benign and malignant tumors, including renal cell carcinoma, pheochromocytoma, and hemangioblastomas.
VHL antibodies are widely used in research to detect VHL expression via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They aid in studying VHL's role in oxygen sensing, tumor suppression, and its interaction with partner proteins (e.g., elongin B/C, cullin-2). Some antibodies specifically recognize wild-type or mutant VHL isoforms, facilitating mechanistic studies in cancer models or clinical diagnostics.
Clinically, VHL antibodies may help assess VHL status in tumors, guiding therapeutic strategies targeting HIF pathways. Their utility extends to exploring VHL's emerging roles in extracellular matrix regulation and cilia function. Ensuring antibody specificity remains crucial due to post-translational modifications and isoform diversity of VHL.
×
